Publications &
Presentations
In our pursuit of scientific advancement we are committed to sharing our acquired knowledge through actively publishing our data in peer-reviewed journals and academic conferences. We aim to provide a deeper understanding through extensive study and analysis on ileal bile acid transporter (IBAT) inhibition, for both the scientific and patient communities.
Research Updates
Featured Presentations & Publications
Improvements in pruritus are associated with growth in patients with progressive familial intrahepatic cholestasis: Data from the MARCH-ON trial
Thompson, et al. Oral Presentation, ESPGHAN 2025.
The relationship between serum bile acids and event-free survival following the use of maralixibat for progressive familial intrahepatic cholestasis (PFIC): Data from the MARCH/MARCH-ON trials
Thompson, et al. Oral Presentation, ESPGHAN 2025.
Improvements in pruritus after maralixibat treatment are associated with improved health-related quality of life for patients with cholestatic liver disease
Gonzales, et al. Oral Presentation, ESPGHAN 2025.
Bile acid subspecies are correlated with pruritus and bilirubin improvement in PFIC patients treated with maralixibat: Data from MARCH and MARCH-ON
Verkade, et al. Oral Presentation, ESPGHAN 2025.
Greater improvements in bilirubin were observed in pruritus responders after maralixibat treatment in patients with PFIC: data from the MARCH/MARCH-ON trials
Thompson, et al. Poster Presentation, ESPGHAN 2025.
Impact of long-term maralixibat treatment on concomitant medication use for the treatment of cholestatic pruritus in Alagille syndrome: Real-world experience in the United States
Tokman, et al. Poster Presentation, ESPGHAN 2025.
Clinical benefits of maralixibat for patients with Alagille syndrome are durable through 7 years of treatment: Data from the MERGE study
Gonzales, et al. Poster Presentation, ESPGHAN 2025.
Volixibat for the treatment of cholestatic pruritus in primary biliary cholangitis: an adaptive, randomized, placebo-controlled phase 2B trial (VANTAGE): 28-week interim analysis
Heneghan, et al. Oral Presentation, EASL 2025.
Latest Research Updates
Filter by topic
- SELECT
- Show all
- Smith Lemli Opitz Syndrome (SLOS)
- Cerebrotendinous Xanthomatosis (CTX)
- Cholbam
- Alagille syndrome
- Biliary atresia
- Health economics and outcomes research
- IBAT inhibition
- LIVMARLI (maralixibat)
- Patient-reported outcomes validation
- Primary biliary cholangitis
- Primary sclerosing cholangitis
- Progressive familial intrahepatic cholestasis
- Volixibat
Until a relevant regulatory agency has approved a Mirum product for a specific disease or population, any scientific presentations regarding such disease or population are not to be considered instruction on the appropriate use of Mirum products or clinical candidates.
